Connect Biopharma Holdings Ltd (NASDAQ:CNTB) — Stock Price
Connect Biopharma Holdings Ltd (NASDAQ:CNTB) is currently trading at $2.15 USD, down 2.49% today. Over the past 52 weeks, shares have ranged between $1.32 and $3.69. This page tracks Connect Biopharma Holdings Ltd's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Connect Biopharma Holdings Ltd market cap and net worth.
Connect Biopharma Holdings Ltd (CNTB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Connect Biopharma Holdings Ltd's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Connect Biopharma Holdings Ltd Income Statement — Revenue, Profit & Earnings by Year
Connect Biopharma Holdings Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $64.00K | $26.03 Million | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | $660.00K | $988.00K | $1.03 Million | — |
| Gross Profit | $64.00K | $26.03 Million | $-988.00K | $-1.03 Million | — |
| Research & Development | $37.80 Million | $29.26 Million | $53.00 Million | $96.63 Million | $80.50 Million |
| SG&A | $20.34 Million | $19.23 Million | $16.05 Million | $20.81 Million | $19.01 Million |
| Total Operating Expenses | $58.14 Million | $48.48 Million | $69.06 Million | $119.32 Million | $98.11 Million |
| Operating Income | $-58.07 Million | $-22.45 Million | $-69.06 Million | $-119.32 Million | $-98.11 Million |
| EBITDA | $-57.37 Million | $-21.79 Million | $-68.34 Million | $-116.74 Million | $-201.36 Million |
| EBIT | $-58.07 Million | $-22.45 Million | $-69.06 Million | $-117.77 Million | $-201.99 Million |
| Interest Expense | — | — | $23.00K | $21.03K | $6.91K |
| Income Before Tax | $-55.28 Million | $-15.40 Million | $-61.99 Million | $-117.79 Million | $-202.00 Million |
| Income Tax Expense | $197.00K | $223.00K | $120.00K | $298.00K | $266.00K |
| Net Income | $-55.48 Million | $-15.63 Million | $-62.11 Million | $-118.09 Million | $-202.27 Million |
Connect Biopharma Holdings Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Connect Biopharma Holdings Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $56.08 Million | $101.28 Million | $127.38 Million | $174.01 Million | $291.05 Million |
| Total Current Assets | $50.93 Million | $96.96 Million | $122.55 Million | $155.78 Million | $275.13 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $6.00 Million | $15.48 Million | $12.64 Million | $73.41 Million | $677.10 |
| Net Receivables | $161.00K | $1.05 Million | $351.00K | $232.00K | $7.41 Million |
| Inventory | — | — | $-13.95 Million | $-6.42 Million | $-6.74K |
| Property, Plant & Equipment | — | — | — | — | $82.16 Million |
| Goodwill | — | — | — | — | $-3.45 Million |
| Total Liabilities | $14.10 Million | $9.12 Million | $25.88 Million | $16.52 Million | $18.80 Million |
| Total Current Liabilities | $13.61 Million | $8.46 Million | $25.29 Million | $15.62 Million | $17.98 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-37.66 Million | $-78.05 Million | $-105.20 Million | $-78.58 Million | $-267.59 Million |
| Total Stockholder Equity | $41.98 Million | $92.17 Million | $101.50 Million | $157.49 Million | $272.26 Million |
| Retained Earnings | $-400.83 Million | $-345.36 Million | $-329.73 Million | $-479.84 Million | $-361.75 Million |
Connect Biopharma Holdings Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Connect Biopharma Holdings Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-51.21 Million | $-23.61 Million | $-47.93 Million | $-99.27 Million | $-544.93 Million |
| Capital Expenditures | $434.00K | $750.00K | $294.00K | $4.28 Million | $47.53 Million |
| Free Cash Flow | $-51.64 Million | $-24.36 Million | $-48.22 Million | $-103.55 Million | $-592.46 Million |
| Investing Cash Flow | $9.82 Million | $-3.45 Million | $75.16 Million | $-83.44 Million | $-34.02 Million |
| Financing Cash Flow | $1.09 Million | $227.00K | $-246.00K | $-91.29K | $1.32 Billion |
| Dividends Paid | — | — | — | — | $243.00K |
| Stock-Based Compensation | $3.73 Million | $6.73 Million | $3.26 Million | $1.01 Million | $57.86 Million |
| Depreciation | $704.00K | $660.00K | $988.00K | $1.01 Million | $4.08 Million |
| Change in Cash | $-39.89 Million | $-27.43 Million | $27.00 Million | $-168.93 Million | $696.80 Million |
Connect Biopharma Holdings Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Connect Biopharma Holdings Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 01, 2026 | -0.27 | -0.28 | +4.60% |
| Dec 31, 2025 | -0.27 | -0.30 | +10.00% |
| Dec 03, 2025 | -0.31 | -0.24 | -31.91% |
| Aug 13, 2025 | -0.23 | -0.22 | -4.55% |
| May 15, 2025 | -0.19 | -0.26 | +26.92% |
| Mar 31, 2025 | -0.42 | 0.00 | — |
| Sep 12, 2023 | -0.54 | -6.92 | +92.20% |